451 related articles for article (PubMed ID: 30637712)
1. Clinical significance of serum EGFR gene mutation and serum tumor markers in predicting tyrosine kinase inhibitor efficacy in lung adenocarcinoma.
Feng LX; Wang J; Yu Z; Song SA; Zhai WX; Dong SH; Yu HS; Zhang Y
Clin Transl Oncol; 2019 Aug; 21(8):1005-1013. PubMed ID: 30637712
[TBL] [Abstract][Full Text] [Related]
2. Correlation between efficacy of the EGFR tyrosine kinase inhibitor and serum tumor markers in lung adenocarcinoma patients.
Pan JB; Hou YH; Zhang GJ
Clin Lab; 2014; 60(9):1439-47. PubMed ID: 25291939
[TBL] [Abstract][Full Text] [Related]
3. Elevated serum CEA levels are associated with the explosive progression of lung adenocarcinoma harboring EGFR mutations.
Gao Y; Song P; Li H; Jia H; Zhang B
BMC Cancer; 2017 Jul; 17(1):484. PubMed ID: 28705152
[TBL] [Abstract][Full Text] [Related]
4. Correlation between EGFR mutations and serum tumor markers in lung adenocarcinoma patients.
Pan JB; Hou YH; Zhang GJ
Asian Pac J Cancer Prev; 2013; 14(2):695-700. PubMed ID: 23621221
[TBL] [Abstract][Full Text] [Related]
5. Monitoring of cyclooxygenase-2 levels can predict EGFR mutations and the efficacy of EGFR-TKI in patients with lung adenocarcinoma.
Li H; Wang Y; Su F; Li J; Gong P
Int J Clin Exp Pathol; 2015; 8(5):5577-83. PubMed ID: 26191267
[TBL] [Abstract][Full Text] [Related]
6. Monitoring of carcinoembryonic antigen levels is predictive of EGFR mutations and efficacy of EGFR-TKI in patients with lung adenocarcinoma.
Zhang Y; Jin B; Shao M; Dong Y; Lou Y; Huang A; Han B
Tumour Biol; 2014 May; 35(5):4921-8. PubMed ID: 24459065
[TBL] [Abstract][Full Text] [Related]
7. Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types.
Park S; Lee SY; Kim D; Sim YS; Ryu JS; Choi J; Lee SH; Ryu YJ; Lee JH; Chang JH
BMC Cancer; 2021 Jan; 21(1):52. PubMed ID: 33430803
[TBL] [Abstract][Full Text] [Related]
8. [Correlation between Serum Tumor Markers and Efficacy of First-line EGFR-TKIs in Patients with Advanced Lung Adenocarcinoma].
Chen H; Yang X; Liu H; Ma K; Zhong J; Dong Z; Zhuo M; Wang Y; Li J; An T; Wu M; Wang Z; Zhao J
Zhongguo Fei Ai Za Zhi; 2017 Sep; 20(9):589-597. PubMed ID: 28935011
[TBL] [Abstract][Full Text] [Related]
9. Early serum tumor marker levels after fourteen days of tyrosine kinase inhibitor targeted therapy predicts outcomes in patients with advanced lung adenocarcinoma.
Chen HJ; Tu CY; Huang KY; Chien CR; Hsia TC
PLoS One; 2020; 15(12):e0240736. PubMed ID: 33306683
[TBL] [Abstract][Full Text] [Related]
10. Volume-based growth tumor kinetics as a prognostic biomarker for patients with EGFR mutant lung adenocarcinoma undergoing EGFR tyrosine kinase inhibitor therapy: a case control study.
Lee JH; Lee HY; Ahn MJ; Park K; Ahn JS; Sun JM; Lee KS
Cancer Imaging; 2016 Mar; 16():5. PubMed ID: 26984681
[TBL] [Abstract][Full Text] [Related]
11. Serum carcinoembryonic antigen levels before initial treatment are associated with EGFR mutations and EML4- ALK fusion gene in lung adenocarcinoma patients.
Wang WT; Li Y; Ma J; Chen XB; Qin JJ
Asian Pac J Cancer Prev; 2014; 15(9):3927-32. PubMed ID: 24935562
[TBL] [Abstract][Full Text] [Related]
12. Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors.
Seki Y; Fujiwara Y; Kohno T; Takai E; Sunami K; Goto Y; Horinouchi H; Kanda S; Nokihara H; Watanabe S; Ichikawa H; Yamamoto N; Kuwano K; Ohe Y
Oncologist; 2016 Feb; 21(2):156-64. PubMed ID: 26768482
[TBL] [Abstract][Full Text] [Related]
13. Cytokeratin 19 fragment predicts the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitor in non-small-cell lung cancer harboring EGFR mutation.
Tanaka K; Hata A; Kaji R; Fujita S; Otoshi T; Fujimoto D; Kawamura T; Tamai K; Takeshita J; Matsumoto T; Monden K; Nagata K; Otsuka K; Nakagawa A; Tachikawa R; Otsuka K; Tomii K; Katakami N
J Thorac Oncol; 2013 Jul; 8(7):892-8. PubMed ID: 23591159
[TBL] [Abstract][Full Text] [Related]
14. Clinical impact of pleural fluid carcinoembryonic antigen on therapeutic strategy and efficacy in lung adenocarcinoma patients with malignant pleural effusion.
Lee J; Lee DH; Park JE; Lee YH; Choi SH; Seo H; Yoo SS; Lee SY; Cha SI; Park JY; Kim CH
Korean J Intern Med; 2024 Mar; 39(2):318-326. PubMed ID: 38351680
[TBL] [Abstract][Full Text] [Related]
15. EGFR mutation L747P led to gefitinib resistance and accelerated liver metastases in a Chinese patient with lung adenocarcinoma.
Yu G; Xie X; Sun D; Geng J; Fu F; Zhang L; Wang H
Int J Clin Exp Pathol; 2015; 8(7):8603-6. PubMed ID: 26339441
[TBL] [Abstract][Full Text] [Related]
16. Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitor Treatment and Salvage Chemotherapy in EGFR-Mutated Elderly Pulmonary Adenocarcinoma Patients.
Tseng YH; Tseng YC; Lin YH; Lee YC; Perng RP; Whang-Peng J; Chen YM
Oncologist; 2015 Jul; 20(7):758-66. PubMed ID: 26054633
[TBL] [Abstract][Full Text] [Related]
17. Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma.
Lin C; Chen X; Li M; Liu J; Qi X; Yang W; Zhang H; Cai Z; Dai Y; Ouyang X
Clin Lung Cancer; 2015 Sep; 16(5):e25-35. PubMed ID: 25801750
[TBL] [Abstract][Full Text] [Related]
18. Correlation between pre-treatment serum carcinoembryonic antigen levels and genotypes in a large population of Chinese people with advanced lung adenocarcinoma.
Liu J; Zhao YQ; Han X; Hu XF; Wu HB; Chen LJ; Song YP
Intern Med J; 2019 May; 49(5):634-643. PubMed ID: 30379408
[TBL] [Abstract][Full Text] [Related]
19. The salvage therapy in lung adenocarcinoma initially harbored susceptible EGFR mutation and acquired resistance occurred to the first-line gefitinib and second-line cytotoxic chemotherapy.
Yang CJ; Hung JY; Tsai MJ; Wu KL; Liu TC; Chou SH; Lee JY; Hsu JS; Huang MS; Chong IW
BMC Pharmacol Toxicol; 2017 May; 18(1):21. PubMed ID: 28486985
[TBL] [Abstract][Full Text] [Related]
20. Digital PCR-Based Detection of EGFR Mutations in Paired Plasma and CSF Samples of Lung Adenocarcinoma Patients with Central Nervous System Metastases.
Huang R; Xu X; Li D; Chen K; Zhan Q; Ge M; Zhou X; Liang X; Guan M
Target Oncol; 2019 Jun; 14(3):343-350. PubMed ID: 31161597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]